Guangdong VTR Bio-Tech Past Earnings Performance
Past criteria checks 0/6
Guangdong VTR Bio-Tech's earnings have been declining at an average annual rate of -40%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 16.4% per year. Guangdong VTR Bio-Tech's return on equity is 1.3%, and it has net margins of 2.8%.
Key information
-40.0%
Earnings growth rate
-42.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -16.4% |
| Return on equity | 1.3% |
| Net Margin | 2.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Guangdong VTR Bio-Tech's (SZSE:300381) Soft Earnings Are Actually Better Than They Appear
May 02
There's No Escaping Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Muted Revenues Despite A 35% Share Price Rise
Apr 30Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Mar 08Revenue & Expenses Breakdown
How Guangdong VTR Bio-Tech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 814 | 23 | 254 | 102 |
| 31 Dec 23 | 796 | -11 | 257 | 100 |
| 30 Sep 23 | 821 | 4 | 285 | 99 |
| 30 Jun 23 | 803 | 10 | 266 | 92 |
| 31 Mar 23 | 931 | 36 | 300 | 90 |
| 01 Jan 23 | 1,174 | 18 | 330 | 100 |
| 30 Sep 22 | 1,558 | -163 | 429 | 107 |
| 30 Jun 22 | 1,775 | -164 | 480 | 126 |
| 31 Mar 22 | 1,918 | -176 | 508 | 133 |
| 01 Jan 22 | 1,892 | -119 | 500 | 130 |
| 30 Sep 21 | 1,772 | 110 | 400 | 127 |
| 30 Jun 21 | 1,868 | 153 | 387 | 127 |
| 31 Mar 21 | 1,910 | 168 | 343 | 128 |
| 31 Dec 20 | 1,915 | 162 | 343 | 123 |
| 30 Sep 20 | 2,077 | 167 | 376 | 121 |
| 30 Jun 20 | 2,111 | 158 | 363 | 120 |
| 31 Mar 20 | 2,109 | 164 | 367 | 111 |
| 31 Dec 19 | 2,048 | 128 | 367 | 112 |
| 30 Sep 19 | 1,930 | 122 | 342 | 102 |
| 30 Jun 19 | 1,834 | 121 | 338 | 93 |
| 31 Mar 19 | 1,774 | 84 | 335 | 94 |
| 31 Dec 18 | 1,768 | 114 | 317 | 91 |
| 30 Sep 18 | 1,766 | 111 | 291 | 155 |
| 30 Jun 18 | 1,652 | 91 | 289 | 135 |
| 31 Mar 18 | 1,528 | 81 | 314 | 112 |
| 31 Dec 17 | 1,499 | 80 | 323 | 94 |
| 30 Sep 17 | 1,496 | 91 | 408 | 0 |
| 30 Jun 17 | 1,527 | 102 | 418 | 0 |
| 31 Mar 17 | 1,558 | 114 | 405 | 0 |
| 31 Dec 16 | 1,512 | 114 | 393 | 0 |
| 30 Sep 16 | 1,278 | 87 | 344 | 0 |
| 30 Jun 16 | 1,066 | 79 | 297 | 0 |
| 31 Mar 16 | 840 | 75 | 253 | 0 |
| 31 Dec 15 | 703 | 72 | 230 | 0 |
| 30 Sep 15 | 534 | 69 | 199 | 0 |
| 30 Jun 15 | 470 | 62 | 186 | 0 |
| 31 Mar 15 | 411 | 53 | 178 | 0 |
| 31 Dec 14 | 360 | 55 | 166 | 0 |
| 30 Sep 14 | 345 | 53 | 157 | 0 |
| 30 Jun 14 | 346 | 54 | 154 | 0 |
| 31 Mar 14 | 352 | 61 | 150 | 0 |
| 31 Dec 13 | 359 | 63 | 150 | 0 |
Quality Earnings: 300381 has a large one-off gain of CN¥7.9M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300381's current net profit margins (2.8%) are lower than last year (3.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300381's earnings have declined by 40% per year over the past 5 years.
Accelerating Growth: 300381's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300381 had negative earnings growth (-37.9%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).
Return on Equity
High ROE: 300381's Return on Equity (1.3%) is considered low.